POLARIS was a study to evaluate different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. The first part, known as the safety lead-in, looked at …

Read more about 'Treatment with encorafenib plus binimetinib study: brain metastasis response rate of over 60% in patients with unresectable metastatic BRAF V600-mutant melanoma with brain metastases'...

Posted in Research; Posted 4 months ago Less than a minute to read